Literature DB >> 32779784

Mutational spectra of SARS-CoV-2 orf1ab polyprotein and signature mutations in the United States of America.

Shuvam Banerjee1,2, Sohan Seal1,3, Riju Dey1,3, Kousik Kr Mondal1, Pritha Bhattacharjee1.   

Abstract

The pandemic COVID-19 outbreak has been caused due to SARS-CoV-2 pathogen, resulting in millions of infections and deaths worldwide, the United States being on top at the present moment. The long, complex orf1ab polyproteins of SARS-CoV-2 play an important role in viral RNA synthesis. To assess the impact of mutations in this important domain, we analyzed 1134 complete protein sequences of the orf1ab polyprotein from the NCBI virus database from affected patients across various states of the United States from December 2019 to 25 April 2020. Multiple sequence alignment using Clustal Omega followed by statistical significance was calculated. Four significant mutations T265I (nsp 2), P4715L (nsp 12), and P5828L and Y5865C (both at nsp 13) were identified in important nonstructural proteins, which function either as replicase or helicase. A comparative analysis shows 265 T→I, 5828 P→L, and 5865Y→C are unique to the United States and not reported from Europe or Asia; while one, 4715 P→L is predominant in both Europe and the United States. Mutational changes in amino acids are predicted to alter the structure and function of the corresponding proteins, thereby, it is imperative to consider the mutational spectra while designing new antiviral therapeutics targeting viral orf1ab.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  COVID-19; ORF1ab polyprotein; SARS-CoV-2; United States of America; mutational spectra; pandemic

Mesh:

Substances:

Year:  2020        PMID: 32779784      PMCID: PMC7436414          DOI: 10.1002/jmv.26417

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   20.693


INTRODUCTION

SARS‐CoV‐2 is the responsible pathogen for pandemic COVID‐19. Positive‐stranded, RNA genomes of coronaviruses are around 27 to 32‐kb in length, of which about 2/3rd encompasses the viral Orf1ab gene and expresses the largest and most complex polyproteins of any RNA viruses. The open reading frame 1 (ORF1), functions as replicase, replicase/transcriptase, or polymerase polyproteins, and is translated into ORF1a (~486 kDa, major product) and ORF1b (~306KDa) polyproteins in the host cell. Virus‐encoded proteinases including Papain‐like protease (PLPs) and 3 C like protease (3CL Pro) cleaves ORF1 into 16 nonstructural proteins (nsps). , ORF1a comprising nsps (nsp 1 to nsp 10) play an important role in coping with cellular stresses and maintaining the functional integrity of the cellular components along with the pivotal roles in viral replication. On the contrary, ORF1b encodes viral RNA‐dependent RNA polymerase (nsp 12), helicase (nsp 13), exonuclease (nsp14), a polyU (Uridylate) specific endonuclease (nsp15), and methyltransferase (nsp16). Hence, the majority of these nsps play an important role in viral pathogenesis and promising target for antiviral drug targeting and vaccine synthesis. At present, the United States is one of the worst affected countries globally in terms of affected individuals and the number of deaths. Until 25 April, the United States was reported to have 860 772 positive cases and 44 053 deaths. This adverse condition led us to investigate the sequence of the viral whole‐genome reported to the NCBI virus database. As on 25 April 2020 (till 12 noon, IST), around 1134 Orf1ab polyprotein sequences have been submitted from the United States alone. Different states of the United States like Washington DC, New York, Connecticut, Idaho, Georgia, etc have uploaded sequences of the Orf1ab polyprotein into the database. As COVID‐19 originated in Wuhan and was found to extend to different parts of the globe with variations in its virulence, it is imperative to identify the mutations that occurred in the Orf1ab polyprotein and consequent impact in protein structure and interaction with the host body. Hence, the present study aims (a) to identify the mutations observed in the orf1ab polyprotein, (b) to predict the conformational changes of SARS‐CoV‐2 polyprotein due to the mutations, and (c) to identify the signature pattern, if any for the United States.

Methodology

ORF1ab protein sequence retrieval from the database

The protein sequences were retrieved from the “NCBI Virus” database, the specific input was “SARS‐CoV‐2”. Then, the output was refined with a sequence length 7050 to 7100, as the length of the target orf1ab polyprotein is 7096. A total of 1307 sequences were retrieved, among them, 125 sequences were from Asia, 42 from Europe, and 1134 solely from the United States.

Screening of submitted sequences and selection of study sample

Incomplete sequences or sequences with undetermined residues (mentioned as X) were eliminated. A total of 867 orf1ab polyprotein complete sequences deposited from 31 different states of the United States were considered for the present study (Group A). All the above‐mentioned sequences from Asia (Group B) and Europe (Group C) were also selected.

Multiple sequence alignment (MSA) and analysis of mutational spectra

Clustal Omega was employed to align multiple sequences of each of the above‐mentioned groups. Then, sequences of Group A were subdivided into 31 subgroups depending on the regional source from which the sequence was originated, and MSA was conducted encompassing all subgroups using the ancestral orf1ab polyprotein sequence of Wuhan (YP_009742608, comprising 7096 residues) as the reference sequence. , Gap opening penalty and gap extension penalty was set at 12 and 2, respectively, to ensure that unnecessary gaps are not created during alignment and alterations are visualized easily. Alignment results were thoroughly screened to find out the exact location of the mutations and alteration linked to that position.

Calculation of statistical significance to detect signature mutations of the United States

The number of occurrences of each mutated variant in Groups A, B, and C were calculated (suppose a, b, and c) and then divided by the total number of sequences submitted under that group (suppose x for Group A, y for Group B, and z for Group C). The proportion of each variant in Group A would be a/x and likewise for the other Groups. Then, the P value was calculated through the Z‐score using the proportion of the mutant and sample size to establish whether the occurrence of that mutant variant in the United States is significantly higher in comparison to Asia and Europe. Two‐tailed P values were calculated using 0.05 as the significance level. Thus, an attempt has been made to identify the signature mutations in the region of orf1ab polyprotein.

Homology modeling and simulation of protein structure

Structures of the associated nonstructural proteins for the wild type were reported at the I‐Tasser server, however, the structures were not available for the varied amino acid (AA) alteration. To identify the alteration, the Homology Modeling method by I‐Tasser was used to generate the secondary structure, which was then superimposed with the wild type using UCSF Chimera and PyMOL for easy visualization and comparison.

RESULTS AND DISCUSSION

To assess the structural variation and identify the signature mutations, if any, among the viral strain(s) identified from the United States, all 1134 sequences, submitted to the NCBI Virus database (December 2019 to 25 April 2020) were retrieved. Following the exclusion criteria mentioned above, 867 complete sequences from 31 different states of the United States were obtained. For each subgroup of Group A, mutations observed in more than 5% studied population were taken into considerations and are shown in Table 1.
Table 1

Region‐wise list of mutations at orf1ab polyprotein in the United States

Name of the stateSample sizeMutation PositionLocation in orf1abAmino acid alterationIndividual with mutated variant% Carrying mutated variant
Washington500265nsp 2T→I20641.2
4715nsp 12P→L22645.2
5828nsp 13P→L25551.0
5865nsp 13Y→C25551.0
New York150265nsp 2T→I11476.0
3884nsp 7S→L2818.7
4715nsp 12P→L13590.0
6245nsp 14A→V2416
Virginia52265nsp 2T→I1732.7
3483nsp 5L→F59.6
4715nsp 12P→L3873.1
5828nsp 13P→L1019.2
5865nsp 13Y→C1019.2
Idaho21265nsp 2T→I1885.7
4715nsp 12P→L1990.5
Connecticut17265nsp 2T→I1164.7
4715nsp 12P→L1482.4
5828nsp 13P→L15.9
5865nsp 13Y→C15.9
California16265nsp 2T→I425.0
4715nsp 12P→L531.3
Massachusetts164715nsp 12P→L1593.8
Georgia13971nsp 3P→L861.5
3606nsp 6L→F215.3
4715nsp 12P→L323.1
6158nsp 14F→L861.5
Utah10265nsp 2T→I440
4715nsp 12P→L550
5828nsp 13P→L440
5865nsp 13Y→C440
Minnesota8265nsp 2T→I337.5
4715nsp 12P→L337.5
5828nsp 13P→L337.5
5865nsp 14Y→C337.5
Florida83606nsp 6L→F112.5
4715nsp 12P→L562.5
5828nsp 13P→L112.5
5865nsp 13Y→C112.5
Illionis7265nsp 2T→I114.3
4715nsp 12P→L342.8
5828nsp 13P→L114.3
5865nsp 13Y→C114.3
Iowa74715nsp 12P→L7100
Pennsylvania74715nsp 12P→L7100
New Hampshire4265nsp 2T→I375
4715nsp 12P→L4100
4764nsp 12L→F125
N. Carolina4265nsp 2T→I125
4715nsp 12P→L125
5828nsp 13P→L125
5865nsp 13Y→C125
Texas32124nsp 3T→I266.7
3606nsp 6L→F266.7
4715nsp 12P→L266.7
Arizona3265nsp 2T→I133.3
4715nsp 12P→L133.3
5828nsp 13P→L266.7
5865nsp 13Y→C266.7
Ohio33606nsp 6L→F133.3
4715nsp 12P→L266.7
Rhode Island3265nsp 2T→I133.3
4715nsp 12P→L3100
Nebraska2392nsp 2G→D2100
876nsp 3A→T2100
4715nsp 12P→L2100
Nevada23606nsp 6L→F150
6669nsp 15A→V150
S. Carolina2971nsp 3P→L2100
5401nsp 13P→L150
6158nsp 14F→L2100
New Orlando2265nsp 2T→I2100
4715nsp 12P→L2100
Kansas14715nsp 12P→L1100
Louisiana1265nsp 2T→I1100
3352nsp 5L→F1100
4715nsp 12P→L1100
Maryland14715nsp 12P→L1100
Missouri14715nsp 12P→L1100
New Jersey14715nsp 12P→L1100
6528nsp 15G→D1100
Hawaii14715nsp 12P→L1100
Wisconsin16679nsp 15L→del1100
Total867
Region‐wise list of mutations at orf1ab polyprotein in the United States A mutation at AA location 265 (Thr→Ile) of nsp2 is observed among ~50% states (subgroups) and 44.2% sequences in the United States (Table 1). Nsp2 is an important domain that takes care of the functional integrity of mitochondria and copes with cellular stress. In addition to this, nsp2 co‐operates with nsp4 in viral replication. Nsp12 is important for its RNA‐dependent RNA polymerase (RdRp) activity and Pro→Leu in 4715 at this domain is a significant alteration, reported in 28 out of 31 states. Nsp 13 functions as a helicase protein, which is a key enzyme in viral replication, and therefore, two mutations, P5828L and Y5865C observed in this domain, are expected to alter in structure‐function and interaction with the host's target site. These two mutations, in particular, are observed and presumed to be linked and found in equal proportions (0.321), among affected individuals from 9 out of 31 states. All these four mutations are widely observed throughout the country, but some mutations are consistently observed in specific regions (Figure 1). Georgia and South Carolina are two neighboring states sharing common borders in the South East region of the United States and both carry the mutant variant Leucine at the position of 971 (P→L) at nsp 3 and 6158 (F→L) at nsp14 in more than 60% cases. Another mutation, 3606 L→F is found in nsp6, and individuals from Florida, Texas, Ohio, Nevada, and Georgia had this mutation with a frequency of more than 10%. Nsp 6 plays a role in the initial induction of autophagosomes from the host endoplasmic reticulum, but gradually limits the expansion of these phagosomes which are unable to deliver viral components to lysosomes. It is important to note here that 3606 L→F mutations were found in Italy while analyzing Group C (present study), which further strengthens our previous reporting.
Figure 1

Mutational hotspots and the corresponding variants found in different geographical regions of the United States

Mutational hotspots and the corresponding variants found in different geographical regions of the United States To study the implication of these mutations, we have compared the prevalence of T265I in the European and Asian populations with that of the United States population. Strikingly, Threonine at 265 is the wild type AA found in all sequences from Europe and 119 out of 125 sequences from Asia. Therefore, the mutated AA Isoleucine is present in only 4.8% patient population in Asia, null in the European population so far, but observed in 44.2% patient population (383 out of 867) in the United States, establishing it to be a signature mutation of the country (P ≤ .0001). Let us consider the mutation 4715 P→L, which is quite common in Europe and present in countries like Spain, France, Greece, etc, and the AA variant Leucine is found in 51.6% (16 out of 31 sequences deposited by European countries). In the United States, the frequency of Leucine is 58.1%, not significantly higher in comparison to Europe (P = .47) but clearly so compared with Asia (<0.0001). However, the mutant Leucine at 4715 is consistently observed in America. Two other most frequent mutations in the United States are 5828 P→L and 5865 Y→C, found in equal proportion (both observed 278 out of 867), presumed to be linked, and exclusively found in the United States, so far (Table 2).
Table 2

The signature mutations of the United States and proportional presence of those mutations in the Asian and European continent

Mutational hotspot in orf1ab ppLocation in orf1ab ppUnited States (Grp 1)Asia (Grp 2) P value (Grp 1 and Grp 2)Europe (Grp 3) P value (Grp 1 and Grp 3)
T265Insp 2383/867 = 0.4426/125  = 0.048<.000010/31 = 0.0<.00001
P4715Lnsp 12 or RdRp504/867 = 0.58114/125 = 0.112<.0000116/31 = 0.516.47152
P5828Lnsp 13 or Helicase278/867 = 0.3210/125 = 0<.000010/31 = 0.0.00014
Y5865Cnsp 13 or Helicase278/867 = 0.3210/125 = 0<.000010/31 = 0.0.00014
The signature mutations of the United States and proportional presence of those mutations in the Asian and European continent The four signature mutations are located in nsp 2, nsp 12, and nsp 13, respectively (Figure 2). Nonstructural protein 2 is assumed to be responsible in the modulation of the host cell survival signaling pathway by interacting with PHB and PHB2 in the host body. , , Change of a polar AA (threonine) to a nonpolar one (isoleucine) makes it hydrophobic and induces structural alteration in that domain, which is observed by simulating the structure of the nsp2 protein harboring mutated allele through homology modeling using I‐Tasser. , ,
Figure 2

Mapping of orf1ab polyprotein and four signature mutations of the United States

Mapping of orf1ab polyprotein and four signature mutations of the United States Structure prediction for wild type nsps is already available in I‐Tasser; which gave us the opportunity to evaluate and superimpose three altered nsp structures (nsp 2, nsp 12, and nsp 13; against the said signature mutations), using UCSF Chimera and PyMOL for clear visualization of the alteration (Figure 3A). RdRp (nsp 12) is responsible for viral replication and transcription. Although SARS‐CoV‐2 and SARS‐CoV share about 79% genome similarity, , with regard to nsp12, the similarity increases as high as 98%, inferring the evolutionary significance of these conserved regions. , RdRp is a major antiviral drug target , and thus the structural alteration due to the mutant AA has important implications. Comparing the superimposed structure of RdRp, four small domains with the altered structure in the mutant sequence have been observed (Figure 3B) and these need to be investigated further. Helicase (nsp 13) is a multifunctional protein having a zinc‐binding domain in the N‐terminus exhibiting RNA and DNA duplex‐unwinding activities with 5′ to 3′ polarity. , Figure 3C exhibits some important structural alterations due to those two mutations present in close proximity near the N‐terminus; including a major structural alteration, where a loop or chain‐like structure is transformed into a helix, found near the N‐terminus of nsp 13. The length of nsp 13 or Helicase protein is 601 (5325‐5925 of orf1ab polyprotein) and the above‐mentioned alteration is found in the location 592 to 598, indicating a possible variation in functional outcome.
Figure 3

Structural comparison of nsp 2, nsp 12, and nsp 13 by superimposing the mutant structure over the wild type; (A) mutant nsp2 with corresponding wild type; (B) mutant nsp12 with corresponding wild type and (C) mutant nsp13 with corresponding wild type, compared through superimposition

Structural comparison of nsp 2, nsp 12, and nsp 13 by superimposing the mutant structure over the wild type; (A) mutant nsp2 with corresponding wild type; (B) mutant nsp12 with corresponding wild type and (C) mutant nsp13 with corresponding wild type, compared through superimposition

CONCLUSIONS

The orf1ab polyprotein of SARS‐CoV‐2 encompasses mutational spectra. Compared with the European and Asian strain(s), four characteristic mutations, 265 T→I (nsp 2), 4715 P→L (nsp 12), 5828 P→L (nsp 13), and 5865Y→C (nsp 13) are observed, which can be considered as a signature pattern for the United States. It is noteworthy to mention here that 5828 P→L and 5865Y→C are exclusively found in the United States until now; whereas 265 T→I is found in very low abundance in Asia (4.42%) and not found at all in Europe. 4715 P→L is commonly found in both the United States (58.1%) and Europe (51.6%) but present in low abundance in Asia (11.2%). 971 P→L and 6158 F→L are frequently observed in Georgia and South Carolina, only representing the South‐East region of the country. All of the four signature mutations caused structural alteration in their respective nonstructural proteins (nsp 2, nsp 12, and nsp 13). Thereby, it is essential to consider the mutational spectra while designing new antiviral therapeutics targeting viral orf1ab.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS

SB had the idea; SB, SS, RD, and KKM did the experiments; SB analyzed the data; SB and PB interpreted the data; SS, RD, KKM, and PB searched the literature; SS and RD did the referencing; SB and PB wrote the manuscript; SS and RD prepared figures; PB supervised the overall study.
  18 in total

1.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

2.  The I-TASSER Suite: protein structure and function prediction.

Authors:  Jianyi Yang; Renxiang Yan; Ambrish Roy; Dong Xu; Jonathan Poisson; Yang Zhang
Journal:  Nat Methods       Date:  2015-01       Impact factor: 28.547

3.  I-TASSER: a unified platform for automated protein structure and function prediction.

Authors:  Ambrish Roy; Alper Kucukural; Yang Zhang
Journal:  Nat Protoc       Date:  2010-03-25       Impact factor: 13.491

4.  Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity.

Authors:  Brian H Harcourt; Dalia Jukneliene; Amornrat Kanjanahaluethai; John Bechill; Kari M Severson; Catherine M Smith; Paul A Rota; Susan C Baker
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 5.  The RNA-dependent-RNA polymerase, an emerging antiviral drug target for the Hendra virus.

Authors:  Tony Velkov; Vincenzo Carbone; Jesmin Akter; Sivashangarie Sivanesan; Jian Li; Travis Beddoe; Glenn A Marsh
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

6.  SARS coronavirus replicase proteins in pathogenesis.

Authors:  Rachel L Graham; Jennifer S Sparks; Lance D Eckerle; Amy C Sims; Mark R Denison
Journal:  Virus Res       Date:  2007-03-29       Impact factor: 3.303

7.  A new coronavirus associated with human respiratory disease in China.

Authors:  Fan Wu; Su Zhao; Bin Yu; Yan-Mei Chen; Wen Wang; Zhi-Gang Song; Yi Hu; Zhao-Wu Tao; Jun-Hua Tian; Yuan-Yuan Pei; Ming-Li Yuan; Yu-Ling Zhang; Fa-Hui Dai; Yi Liu; Qi-Min Wang; Jiao-Jiao Zheng; Lin Xu; Edward C Holmes; Yong-Zhen Zhang
Journal:  Nature       Date:  2020-02-03       Impact factor: 49.962

8.  Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation.

Authors:  Nuala A O'Leary; Mathew W Wright; J Rodney Brister; Stacy Ciufo; Diana Haddad; Rich McVeigh; Bhanu Rajput; Barbara Robbertse; Brian Smith-White; Danso Ako-Adjei; Alexander Astashyn; Azat Badretdin; Yiming Bao; Olga Blinkova; Vyacheslav Brover; Vyacheslav Chetvernin; Jinna Choi; Eric Cox; Olga Ermolaeva; Catherine M Farrell; Tamara Goldfarb; Tripti Gupta; Daniel Haft; Eneida Hatcher; Wratko Hlavina; Vinita S Joardar; Vamsi K Kodali; Wenjun Li; Donna Maglott; Patrick Masterson; Kelly M McGarvey; Michael R Murphy; Kathleen O'Neill; Shashikant Pujar; Sanjida H Rangwala; Daniel Rausch; Lillian D Riddick; Conrad Schoch; Andrei Shkeda; Susan S Storz; Hanzhen Sun; Francoise Thibaud-Nissen; Igor Tolstoy; Raymond E Tully; Anjana R Vatsan; Craig Wallin; David Webb; Wendy Wu; Melissa J Landrum; Avi Kimchi; Tatiana Tatusova; Michael DiCuccio; Paul Kitts; Terence D Murphy; Kim D Pruitt
Journal:  Nucleic Acids Res       Date:  2015-11-08       Impact factor: 16.971

9.  De novo design of protein peptides to block association of the SARS-CoV-2 spike protein with human ACE2.

Authors:  Xiaoqiang Huang; Robin Pearce; Yang Zhang
Journal:  Aging (Albany NY)       Date:  2020-06-16       Impact factor: 5.682

10.  Protein Structure and Sequence Reanalysis of 2019-nCoV Genome Refutes Snakes as Its Intermediate Host and the Unique Similarity between Its Spike Protein Insertions and HIV-1.

Authors:  Chengxin Zhang; Wei Zheng; Xiaoqiang Huang; Eric W Bell; Xiaogen Zhou; Yang Zhang
Journal:  J Proteome Res       Date:  2020-03-24       Impact factor: 4.466

View more
  11 in total

1.  Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission.

Authors:  Alba Escalera; Ana S Gonzalez-Reiche; Sadaf Aslam; Ignacio Mena; Manon Laporte; Rebecca L Pearl; Andrea Fossati; Raveen Rathnasinghe; Hala Alshammary; Adriana van de Guchte; Keith Farrugia; Yiren Qin; Mehdi Bouhaddou; Thomas Kehrer; Lorena Zuliani-Alvarez; David A Meekins; Velmurugan Balaraman; Chester McDowell; Jürgen A Richt; Goran Bajic; Emilia Mia Sordillo; Marion Dejosez; Thomas P Zwaka; Nevan J Krogan; Viviana Simon; Randy A Albrecht; Harm van Bakel; Adolfo García-Sastre; Teresa Aydillo
Journal:  Cell Host Microbe       Date:  2022-01-21       Impact factor: 31.316

Review 2.  The Emergence of SARS-CoV-2 Variants With a Lower Antibody Response: A Genomic and Clinical Perspective.

Authors:  Suvro Biswas; Shafi Mahmud; Mohasana Akter Mita; Shamima Afrose; Md Robiul Hasan; Gobindo Kumar Paul; Mst Sharmin Sultana Shimu; Md Salah Uddin; Shahriar Zaman; Moon Nyeo Park; Abolghasem Siyadatpanah; Ahmad J Obaidullah; Md Abu Saleh; Jesus Simal-Gandara; Bonglee Kim
Journal:  Front Med (Lausanne)       Date:  2022-05-06

3.  Search and sequence analysis tools services from EMBL-EBI in 2022.

Authors:  Fábio Madeira; Matt Pearce; Adrian R N Tivey; Prasad Basutkar; Joon Lee; Ossama Edbali; Nandana Madhusoodanan; Anton Kolesnikov; Rodrigo Lopez
Journal:  Nucleic Acids Res       Date:  2022-04-12       Impact factor: 19.160

4.  Mutational spectra of SARS-CoV-2 isolated from animals.

Authors:  Ahmed Elaswad; Mohamed Fawzy; Shereen Basiouni; Awad A Shehata
Journal:  PeerJ       Date:  2020-12-18       Impact factor: 2.984

5.  Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage.

Authors:  Suruchi Gupta; Prosenjit Paul; Ravail Singh
Journal:  Gene Rep       Date:  2021-05-05

6.  Genome sequence analysis of SARS-COV-2 isolated from a COVID-19 patient in Erbil, Iraq.

Authors:  Bashdar Mahmud Hussen; Dana Khdr Sabir; Yasin Karim; Karzan Khawaraham Karim; Hazha Jamal Hidayat
Journal:  Appl Nanosci       Date:  2022-02-07       Impact factor: 3.869

Review 7.  Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants.

Authors:  Jialing Yin; Chengcheng Li; Chunhong Ye; Zhihui Ruan; Yicong Liang; Yongkui Li; Jianguo Wu; Zhen Luo
Journal:  Comput Struct Biotechnol J       Date:  2022-01-31       Impact factor: 7.271

8.  The preparation of N-IgY targeting SARS-CoV-2 and its immunomodulation to IFN-γ production in vitro.

Authors:  Jinglu Lyu; Lirong Bao; Xin Shen; Caixia Yan; Cheng Zhang; Wei Wei; Yutao Yang; Jia Li; Jiajia Dong; Liying Xiao; Xuedong Zhou; Yan Li
Journal:  Int Immunopharmacol       Date:  2021-05-19       Impact factor: 5.714

9.  Mutational spectra of SARS-CoV-2 orf1ab polyprotein and signature mutations in the United States of America.

Authors:  Shuvam Banerjee; Sohan Seal; Riju Dey; Kousik Kr Mondal; Pritha Bhattacharjee
Journal:  J Med Virol       Date:  2020-08-25       Impact factor: 20.693

10.  Identification of novel mutations in SARS-COV-2 isolates from Turkey.

Authors:  Shazia Rehman; Tariq Mahmood; Ejaz Aziz; Riffat Batool
Journal:  Arch Virol       Date:  2020-10-06       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.